Literature DB >> 6469428

Half-strength atenolol-chlorthalidone combination (tenoretic mite) in the treatment of elderly hypertensive patients.

R Fogari, A Zoppi.   

Abstract

The antihypertensive efficacy and tolerance of a new fixed combination of 50 mg atenolol and 12.5 mg chlorthalidone (Tenoretic Mite, TM) was studied in 37 patients with arterial hypertension, aged 61-80 years (mean, 70.2 years), who had been randomized to either 50 mg atenolol or 12.5 mg chlorthalidone for a 4-week period. At the end of this period, the fixed combination of atenolol and chlorthalidone was given to all patients for 6 months at a dose of one tablet daily in the morning. In both atenolol- and chlorthalidone-pretreated patients, treatment with the fixed combination resulted in a further significant drop in blood pressure, whereas the heart rate decreased only in the latter group. The mean blood pressure reduction achieved by the fixed combination was 30/15 mmHg in the standing position. Serum potassium levels significantly increased with the fixed combination compared with values on chlorthalidone alone. Unwanted effects were rare, and their frequency tended to decrease over time. In conclusion, the fixed combination of 50 mg atenolol plus 12.5 mg chlorthalidone tested in this study proved highly effective in lowering elevated blood pressure values in a population of elderly hypertensive patients treated over a 6-month period without noticeable unwanted effects.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6469428

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Ther Toxicol        ISSN: 0174-4879


  2 in total

1.  The efficacy and tolerability of atenolol, nifedipine, and their combination in the management of hypertension.

Authors:  N N Stanley; J L Thirkettle; M P Varma; H Larkin; I D Heath
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

2.  Efficacy and tolerability of atenolol, nifedipine and their combination in the management of hypertension.

Authors:  N N Stanley; J L Thirkettle; M P Varma; H Larkin; I D Heath
Journal:  Drugs       Date:  1988       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.